Recently, Suzhou Junji Gene Technology Co., Ltd. (hereafter referred to as "Junji Gene") declared the successful closure of its Series A funding round, amassing nearly 100 million yuan. This funding round was co-led by Tianhui Capital, Jinqiao Fund, and Jinhai Venture Capital, with additional support from Guanggu Industrial Investment. WinX Capital played the role of exclusive financial advisor in this transaction. The capital raised in this round will be predominantly allocated towards the enhancement and modernization of fully automated production lines, the continuous iteration of core technology research and development, the expansion of the team, and the global market outreach, thereby further propelling the worldwide deployment of automated gene technology applications. Centered around the principles of "automation + intelligence", Junji Gene has constructed a comprehensive, one-stop gene technology application platform that encompasses gene sequencing, synthesis, editing, and expression. This platform offers automated solutions tailored to individual scenarios as well as end-to-end services for sectors such as synthetic biology and biopharmaceuticals.